An experimental injection is asking whether the immune system can be nudged into recognising a skin tumour more effectively. The latest results are promising enough to justify further testing, but they leave a crucial question unresolved: how well would the approach work compared with established care?
On 30 September 2026, Highlight Therapeutics announced preliminary results from SPOTLIGHT-204, a Phase IIb study of BO-112 in basal cell carcinoma, a common skin cancer. This is a human clinical study, rather than a cell-culture experiment, but BO-112 remains investigational and unapproved. Company results announcement
Featured image: Ousa Chea / Unsplash. Representative photograph; it does not depict the specific study, product or facility described.
What the response figure measures
The study enrolled 50 people. Among 46 evaluable patients, 28 met its combined visual and tissue-based response endpoint at week 24, giving the reported 61% response rate. That endpoint included responses of Grade 3 or better; it should not be read as meaning that 61% of patients were cured. Endpoint and analysis population
The trial used three weekly injections into the lesions, followed by complete surgical removal at week 24. Tissue examination helped assess the result. The design therefore does not establish that patients can safely avoid surgery, even though a less invasive option is part of the developer’s ambition. Treatment and assessment schedule
RNA as an immune alarm
BO-112 contains double-stranded RNA packaged in nanoparticles. The intended effect is to activate the cell’s antiviral alarm systems and encourage an immune response against the tumour. “Intralesional” simply means that the injection goes directly into the lesion. How BO-112 is designed to work
The study had one treatment group and no randomised comparison group. That makes it useful for detecting a signal and planning a larger trial, but limits conclusions about comparative benefit. A response at one assessment also leaves questions about how long the effect lasts.
The next test needs a stronger comparison
The company reported no serious adverse events or severe treatment-related events of Grade 3 or higher in this study. A small cohort cannot exclude uncommon harms, and topline results are a preliminary account rather than a complete peer-reviewed clinical paper. Safety and reporting limitations
The meaningful next step is evidence that connects tumour response with durable control, safety and patient outcomes. This study advances that investigation; it does not settle whether the injection can replace a procedure.
Leave a Reply